Results 41 to 50 of about 10,318 (317)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups [PDF]

, 2022
INTRODUCTION: This post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with
Bodholdt, Ulrik, Catarig, Andrei Mircea, Catrina, Sergiu, Clark, Alice, Ekberg, Neda Rajamand, Erhan, Umut, Holmes, Patrick, Knudsen, Søren Tang, Liutkus, Joanne, Rudofsky, Gottfried, Sathyapalan, Thozhukat, Schultes, Bernd, Yale, Jean François   +12 more
core   +1 more source

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China

Frontiers in Endocrinology, 2022
BackgroundsRobust evidence have demonstrated the beneficial effect of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in T2D patients with cardiovascular diseases and chronic kidney disease ...
Cao Li, Shanshan Guo, Jiping Huo, Yiming Gao, Yiming Gao, Yilong Yan, Yilong Yan, Zhigang Zhao   +7 more
doaj   +1 more source

Data mining approach to estimate the duration of drug therapy from longitudinal electronic medical records [PDF]

, 2017
Background: Electronic Medical Records (EMRs) from primary/ ambulatory care systems present a new and promising source of information for conducting clinical and translational research.
Arandelovic, Ognjen, Montvida, Olga, Paul, Sanjoy K., Reiner, Edward   +3 more
core   +1 more source

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

Military Medical Research, 2022
Abstract Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM, the Food
Michael Razavi, Ying-Ying Wei, Xiao-Quan Rao, Ji-Xin Zhong   +3 more
openaire   +3 more sources

GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway

Journal of Diabetes Research, 2022
Background. GLP-1 receptor agonists (GLP-1RA) are common clinical agents that are clinically protective against diabetic complications, such as diabetic retinopathy (DR).
Liufeng Wei, Weiwei Mo, Shanshan Lan, Haiyan Yang, Zhenxing Huang, Xinghuan Liang, Li Li, Jing Xian, Xuemei Xie, Yingfen Qin, Faquan Lin, Zuojie Luo   +11 more
doaj   +1 more source

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysisResearch in context

EClinicalMedicine, 2023
Summary: Background: Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA plus sodium glucose cotransporter-2 inhibitors [SGLT-2i] combinations ...
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F.M. Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino   +10 more
doaj   +1 more source

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus [PDF]

, 2018
Bone fractures are common comorbidities of type 2 diabetes mellitus (T2DM). Bone fracture incidence seems to develop due to increased risk of falls, poor bone quality and/or anti-diabetic medications.
B. Bouvard, B. Gobron, D. Chappard, G. Mabilleau   +3 more
core   +3 more sources

Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study. [PDF]

, 2016
OBJECTIVES: To assess trends in prescribing practices of antidiabetic agents and glycaemic control in patients with type 2 diabetes mellitus (T2DM).
Franch Nadal, Josep, Mata Cases, Manel, Mauricio Puente, Dídac, Real, Jordi   +3 more
core   +2 more sources

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background We investigated the effects of insulin, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i), and their combination on vascular and cardiac function of patients with type 2 diabetes mellitus.
Ignatios Ikonomidis, George Pavlidis, John Thymis, Dionysia Birba, Aimilianos Kalogeris, Foteini Kousathana, Aikaterini Kountouri, Konstantinos Balampanis, John Parissis, Ioanna Andreadou, Konstantinos Katogiannis, George Dimitriadis, Aristotelis Bamias, Efstathios Iliodromitis, Vaia Lambadiari   +14 more
doaj   +1 more source

Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong

Cardiovascular Diabetology, 2023
Background There are limited data on head-to-head comparative risk of stroke between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).
David Tak Wai Lui, Eric Ho Man Tang, Tingting Wu, Ivan Chi Ho Au, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan, Carlos King Ho Wong   +7 more
doaj   +1 more source